Current and Emerging Issues in Wilsons Disease
NEJM 389:922-938, Roberts,E.A. & Schilsky, M.L., 2023
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Neurol 97:e1367-e1381, Gaig, C.,et al, 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Spontaneous Limb Withdrawal Heralding Hyperacute Stroke or Stroke Worsening
Neurol 87:636-638, Delgado, M.G.,et al, 2016
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
On-Road Driving Impairments in Huntingtons Disease
Neurol 82:956-962, Devos, H.,et al, 2014
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Pilot Randomized Trial of Outpatient Cardiac Monitoring After Cryptogenic Stroke
Stroke 44:528-530, Kamel, H.,et al, 2013
Head Drop in Huntington Disease: Insights into the Pathophysiology
Neurol 81:769-770, Morgante, F.,et al, 2013
Immunotherapy-Responsive Chorea as the Presenting Feature of LGI1-Antibody Encephalitis
Neurol 79:195-196, Tofaris,G.K.,et al, 2012
CAG Repeat Expansion in Huntington Disease Determines Age at Onset in a Fully Dominant Fashion
Neurol 78:690-695, Lee,J.M.,et al, 2012
Evidence-Based Path to Newborn Screening for Duchenne Muscular Dystrophy
Ann Neurol 71:304-313, Mendell,J.R.,et al, 2012
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Acquired Neurosyphilis Presenting as Movement Disorders
Mov Disord 27:690-695, Shah, B.B. & Lang, A.E., 2012
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
Revascularization of Asymptomatic High-Grade Carotid Stenosis Is Still Indicated in Some Cases
Stroke 42:1152-1153, 1156, Markus,H., 2011
Revascularization of Asymptomatic High-Grade Stenosis Is Not Indicated With Contemporary Stroke Prevention Medical Therapy
Stroke 42:1154-1155, 1156, Ingall,T.J., 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
A Multidisciplinary Study of Patients with Early-Onset PD with and Without Parkin Mutations
Neurol 72:110-116,106, Lohmann,E.,et al, 2009
High-Resolution Diffusion Tensor Imaging in the Substantia Nigra of De Novo Parkinson Disease
Neurol 72:1378-1384,1374, Vaillancourt,D.E.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
Screening for Intracranial Aneurysms in ADPKD: A More Accurate Risk Assignment Model Is Needed
BMJ 339:706-707, Ong,A., 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Association of Parental Dementia With Cognitive and Brain MRI Measures in Middle-Aged Adults
Neurol 73:2071-2078, 2054, Debette,S.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Biochemical Markers in Persons With Preclinical Familial Alzheimer Disease
Neurol 71:85-92,78, Ringman,J.M.,et al., 2008
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Prodromal Alzheimers Disease: Successive Emergence of the Clinical Symptoms
Ann Neurol 64:492-498,479, Amieva,H.,et al, 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Dementia Screening in Primary Care: Is It Time?
JAMA 298:2409-2411, Brayne,C.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Neural Transplantation in Huntington Disease: Long-Term Grafts in Two Patients
Neurol 68:2093-2098, Keene,C.D.,et al, 2007
A Review of Screening Tests for Cognitive Impairment
JNNP 78:790-799, Cullen,B.,et al, 2007
Wilson Disease: Description of 282 Patients Evaluated Over 3 Decades
Medicine 86:112-121, Taly,A.B., et al, 2007
Outcome of Neonatal Screening for Medium-Chain acyl-CoA Dehydrogenase Deficiency in Australia: A Cohort Study
Lancet 369:37-42,5, Wilcken,B.,et al, 2007